Search

everythinglearnresearchcommunity

for

Search:↓

A 24-year-old shared three months of progress using dutasteride, minoxidil, and biotin for hair loss. The post includes progress pictures and discusses the effectiveness of these treatments.

PP405 is a promising molecule that may reactivate dormant hair follicles, potentially offering a new treatment for hair loss. It is in phase 2 trials, with possible availability between 2027 and 2030.

The conversation discusses hair loss treatments, specifically Breezula, Minoxidil, finasteride, and RU58841. Participants express curiosity about Breezula's safety and its steroidal nature.

HMI 115 is being discussed as a potential hair loss treatment, with skepticism due to past disappointments like cosmeRNA, brezula, and pyrilutamide. The user is questioning if they should be hopeful for new developments in the next six years.

A phase 3 trial for Breezula (clascoterone solution) to treat male pattern hair loss has been listed, with 726 participants and a completion date of January 2025. Other treatments mentioned include Aneira Pharma's combination of minoxidil and latanoprost, Triple Hair's combination of minoxidil, latanoprost, and finasteride, and a new microneedling and LLLT device called StimuSIL.

Hair transplant success largely depends on individual biology, with many patients needing multiple procedures to achieve satisfactory density. Even top surgeons can't guarantee results, and many people use additional treatments like Minoxidil and Finasteride.

The conversation discusses hair regrowth using Scandinavian Biolabs products, biotin pills, a dermaroller, rosemary oil, and a silicone head cleaner. The user observes weak hair regrowth and seeks opinions on the results.

The user is undergoing Mesotherapy and Low-Level Laser Therapy for hair loss, with plans for multiple sessions. They are also using oral finasteride, topical minoxidil, dutasteride, and hair fibers.

A user developed AI software to simulate hair transplants on photos, helping people visualize potential results. The tool offers photo-realistic renderings but advises caution regarding exact outcomes due to various factors.

Balding scalps have more androgen receptors, leading to increased TGF-beta, which causes blood vessel loss and hair follicle miniaturization. Blocking androgen signaling and TGF-beta may help prevent hair loss.

HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.

The conversation discusses promising hair cloning research seeking commercialization partners. Cultured hairs formed with pigment, indicating positive progress.

Users discuss potential game-changing hair loss treatments in the next 10 years. Some mention KX-826, SCUBE3, and stem cells as promising options, while others express doubt due to past disappointments and lack of focused research.

A user created a web app called TrichoMetrics to track hair loss using photos and metrics like density and thinning. The app supports tracking treatments like Minoxidil and finasteride, with features for setting baselines, comparing progress, and logging treatment adherence.

Melatonin, gingko biloba, and biotin are effective for treating hair loss with good tolerability. Alternatives like dutasteride, minoxidil, and other peptides are also discussed.

A group buy for hair loss treatments including Harmine 19a, TM5614, Abiraterone Acetate, and others. A compound, BMS-202, that can potentially reverse gray hair is also mentioned.

Rhamnose may promote hair growth and pigmentation, suggesting it as a potential hair loss treatment. The conversation discusses its potential alongside known treatments like Minoxidil, finasteride, and RU58841.

RepliCel has purchased Trichoscience, and they have a video about hair multiplication. The conversation also mentions treatments like Minoxidil, finasteride, and RU58841.

The conversation discusses the potential of Replicel/Shiseido treatment for hair loss, questioning its effectiveness, whether it grows new follicles, and its market release timeline. It also compares Replicel to other competitors like Kyocera/RIKEN/Tsuji.

Amplifica is testing a compound called AMP-303 for hair loss, but it's not Scube3 or osteopontin. The timing for the results from the clinical trial is unknown.

The conversation discusses disappointment over only receiving a financial report from Cassiopea instead of trial results for Breezula/CB-03-01, a hair loss treatment. However, there is optimism as the company is advancing Breezula into Phase III trials for men, starting trials for women, and submitting an NDA for their acne product, Winlevi.

A user is seeking a European supplier for a 3-in-1 hair loss medication containing Minoxidil, Finasteride, and Biotin. Suggestions include using forwarding services and a UK-based provider, with discussions on potential import taxes.

Gene editing for hair loss is not yet viable due to technological and economic challenges. Current treatments like Minoxidil, finasteride, and hair transplants remain the most practical options.

Minoxidil, finasteride, and RU58841 are discussed as treatments for hair loss. Concerns about AI-generated content accuracy and misinformation are raised.

Keratin microspheres may offer additional mechanisms to combat hair loss compared to minoxidil. The process to create these microspheres is relatively simple and can be done at home with basic equipment.

Cbum's hair transplant is criticized for looking unnatural and not blending well, with some suggesting better results were expected given his resources. Discussions also cover the effects of steroids and finasteride on hair loss and muscle growth.

CB 03 01 (Breezula) was tried for hair loss but showed no significant improvement, with issues in dissolving and application. Finasteride and dutasteride remain the most effective treatments, while minoxidil is also used; CB's effectiveness is questioned, and topical alternatives like bicalutamide are considered.

The conversation is about a user seeking information on a clinical trial by Amplifica - Scube3 for Androgenetic Alopecia (AGA). The user is unsure if it's a formal phase 1 study.

Amplifica's progress on Scube3 is unclear, with no recent updates. The conversation also mentions Minoxidil, finasteride, and RU58841 as hair loss treatments.

Concerns about CosmeRNA safety mechanisms and potential side effects. Discussion includes comparisons to Fluridil and questions about nanoparticle specificity and siRNA stability.